In inflammatory bowel disease, IL-17A has been shown to be protective for the barrier (Uluçkan and Wagner, 2017), and animal studies similarly suggest that IL-17A and its receptor maintain the skin barrier function (Naik et al., 2015, Floudas et al., 2017). Here, IL17A is linked to inflammatory bowel disease.